Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency

Current Pharmacogenomics

Volumn 5, Issue 1, 2007, Pages 31-38

  Hsiao, Hui Hua ^a,b   Lin, Sheng Fung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase gene (DPYD); DPD protein; Missense mutation; Polymorphisms

Indexed keywords

ADENINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GUANINE; PYRIMIDINE;

ALLELE; AMINO ACID METABOLISM; AMINO ACID SUBSTITUTION; BREATH ANALYSIS; CHROMOSOME 1P; CLINICAL FEATURE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG FATALITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME STRUCTURE; EUROPE; EXON; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MISSENSE MUTATION; NONSENSE MUTATION; PHARMACOGENETICS; POPULATION GENETICS; RACE DIFFERENCE; REGULATORY MECHANISM; REVIEW; TREATMENT OUTCOME; URINALYSIS;

EID: 33947102998     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016007780077176     Document Type: Review

References (76)

1. Ahluwalia, R.; Freimuth, T.; McLead, H. L. and Marsh, S. (2003) Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin. Chem. 49, 1661-1664.
2. Chazal, M.; Etienne, M. C.; Renee, N.; Bourgeon, A.; Richelme, H. and Milano, G. (1996) Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res. 2, 507-510.
3. Celik, I.; Kars, A. L.; Guc, D. L.; Tekuzman, G. and Ruacan, S. (2002) Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest. 20, 333-339.
4. Collie-Duguid, S. R.; Etienne, M. C.; Milano, G. and Mcleod, H. (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10, 217-223.
5. Diasio, R. B.; Beavers, T. L. and Carpenter, J. T. (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81, 47-51.
6. Diasio, R. B. and Harris, B. E. (1989) Clinical pharmacology of 5-flurorouracil. Clin. Pharmacokinet. 16, 215-237.
7. Dobritzsch, D.; Schneider, G.; Schnackerz, K. D. and Lindqvist, Y. (2001) Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 20, 650-660.
8. Etienne, M. C.; Lagrange, J. L.; Dassonville, O.; Fleming, R.; Thyss, A.; Renee, N.; Schneider, M.; Demard, F. and Milano, G. (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12, 2248-2253.
9. Etienne, M. C.; Chatelut, E.; Pivot, X.; Lavit, M.; Pujol, A.; Canal, P. and Milano, G. (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur. J. Cancer 34, 92-97.
10. Etienne, H.; Johnson, M. R.; Okamoto, Y. and Diasio, R. (2003) Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res. 9, 3021-3028.
11. Ezzeldin, H.; Okamoto, Y.; Johnson, M. R. and Diasio, R. B. (2002) A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal. Biochem. 306, 63-73.
12. Ezzeldin, H.; Johnson, M. R.; Okamoto, Y. and Diasio, R. B. (2003) Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res. 9, 3021-3028.
13. Ezzeldin, H. and Diasio, R. B. (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following, 5-fluorouracil administration. Clin. Colorectal Cancer 4, 181-189.
14. Ezzeldin, H.; Lee, A. M.; Mattison, L. K. and Diasio, R. B. (2005) Methylation of the DPYD promoter. An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 11, 8699-8705.
15. Fleming, R. A.; Milano, G.; Thyss, A.; Etienne, M. C.; Renee, N.; Schneider, M. and Demard, F. (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 53, 2899-2902.
16. Furuhata, T.; Kawakami, M.; Okita, K.; Kimura, Y.; Kihara, C.; Tsuruma, T.; Ohnura, T.; Yamaguchi, K.; Hata, F.; Katsuramaki, T.; Sasaki, K. and Hirata, K. (2006) Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. J. Exp. Clin. Cancer Res. 25, 79-82.
17. Grem, J. L.; Yee, L. K.; Venzon, D. J.; Takimoto, C. H. and Allegra, C. J. (1997) Inter and intra-individual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol. 40, 117-125.
18. Hamdy, S. I.; Hiratsuka, M.; Narahara, K.; El-Enany, M.; Moursi, N.; Ahmed, M. S. E. and Mizugaki, M. (2002) Allele and genotype frequency of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 53, 596-603.
19. Harris, B. E.; Song, R.; Soong, S. J. and Diasio, R. B. (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50, 197-201.
20. Harris, B. E.; Carpenter, J. T. and Diasio, R. B. (1991) Severe-5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68, 499-501.
21. Hasegawa, T.; Kim, H. S.; Fakushima, M. and Vataya, Y. (2005) Sequence analysis of the 5′-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil. Nucleosides Nucleotides Nucleic Acids 24, 233-242.
22. Heggie, G. D.; Sommadossi, J.-P.; Cross, D. S.; Huster, W. J. and Diasio, R. B. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile. Cancer Res. 47, 2203-2206.
23. Hsiao, H. H.; Yang, M. Y.; Chang, J. G.; Liu, Y. C.; Liu, T. C.; Chang, C. S.; Chen, T. P. and Lin, S. F. (2004) Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother. Pharmacol. 53, 445-451.
24. Jiang, W.; Lu, Z.; He, Y. and Diasio, R. B. (1997) Dihydropyrimidine dehydrogenase activity in hepatocelular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 3, 395-399.
25. Johnson, M. R.; Wang, K.; Tillmanns, S.; Albin, N. and Diasio, R. B. (1997a) Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 57, 1660-1663.
26. Johnson, M. R.; Yan, J.; Shao, L.; Albin, N. and Diasio, R. B. (1997b) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J. Chromatogr. 696, 183-191.
27. Johnson, M. R. and Diasio, R. B. (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluroruracil. Adv. Enzyme Regul. 41, 151-157.
28. Johnson, M. R.; Wang, K. and Diasio, R. B. (2002) Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8, 768-774.
29. Katharina, S.; Riemer, S.; Kates, R.; Ulrich, T.; Lutz, V.; Harbeck, N.; Schmitt, M.; Kiechle, M.; Diasiao, R. B. and Gross, E. (2005) Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 11, 5886-5892.
30. Kouwaki, M.; Hamajima, N.; Sumi, S.; Nonaka, M.; Ssaki, M.; Dobashi, K.; Kidouchi, K.; Togari, H. and Wada, Y. (1998) Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-Fluorouracil toxicity. Clin. Cancer Res. 4, 2999-3004.
31. Kubota, T. (2003) 5-Fluorouracil and dihydropyrimidine dehydrogenase. Int. J. Clin. Oncol. 8, 127-131.
32. Lu, Z.; Zhang, T. and Diasio, R. B. (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53, 5433-5438.
33. Lu, Z.; Zhang, R. and Diasio, R. B. (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin. Pharmacol. Ther. 58, 512-522.
34. Lu, Z.; Zhang, T.; Carpenter, J. T. and Diasio, R. B. (1998) Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 4, 325-329.
35. Maring, J. G.; Van Kuilenburg, A. B. P.; Haasjes, J.; Piersma, H.; Groen, H. J.; Uges, D. R.; Van Gennip, A. H. and De Vries, E. G. (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer 86, 1028-1033.
36. Mattison, L. K.; Johnson, M. R. and Diasio, R. B. (2002a) A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservative of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 12, 133-144.
37. Mattison, L. k.; Soong, R. and Diasio, R. B. (2002b) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3, 485-492.
38. 13C-uracil breath test. Clin. Cancer Res. 10, 2653-2658.
39. Mattison, L. K.; Fourie, J.; Hirao, Y.; Koga, T.; Desmond, R. A.; King, J. R.; Shimizu, T. and Diasio, R. B. (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 plasma [2-13C] dihydrouracil. Clin. Cancer Res. 15, 549-555.
40. McLeod, H. L.; Collie-Duguid, E. S. R.; Vreken, P.; Johnson, M. R.; Wei, X.; Sapone, A.; Diasio, R. B.; Fernandez-Salguero, P.; VanKuilenburg, A. B. P.; Van Gennip, A. H. and Gonzalez, F. J. (1998) Nomenclature for human DPYD alleles. Pharmacogenetics 8, 455-459.
41. Milano, G. and Etienne, M. (1994) Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res. 14, 2295-2297.
42. Naguib, G. N. M. and El Kouin, M. H.,(1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45, 5405-5412.
43. Nauck, M.; Gierens, H.; Marz, W. and Wieland, H. (2001) Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymidine uraciluria using fluorogenic hybridization probes. Clin. Biochem. 34, 103-105.
44. Noguchi, T.; Tanimoto, K.; Shimokuni, T.; Ukon, K.; Tsujimoto, H.; Fukushima, M.; Noguchi, T.; Kawahara K.; Hiyama, K. and Nishiyama, M. (2004) Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity of 5-fluorouracil in cancer cells. Clin. Cancer Res. 10, 7100-7107.
45. Ogura, K.; Ohnuma, T.; Minamide, Y.; Mizuno, A.; Nishiyama, T.; Nagashima, S.; Kanomaru, M.; Hiratsuka, A.; Watabe, T. and Uenmatsu, T. (2005) Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin. Cancer Res. 11, 5104-5111.
46. Omura, K. (2003) Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FH-based chemotherapy: Mutations in the DPD gene and DP inhibitory fluoropyrimidines. Int. J. Clin. Oncol. 8, 132-138.
47. Porsin, B.; Formento, J. L.; Filipski, E.; Etienne, M. C.; Francoual, M.; Renee, N.; Magne, N.; Levi, F. and Milano, G. (2003) Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur. J. Cancer 39, 822-828.
48. Raida, M.; Schwabe, W.; Hausler, P. L.; Van Kuilenburg, A. B. P.; Van Gennip, A. H.; Behnke, D. and Hoffken, D. (2001) Prevalence of common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intro 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7, 2832-2839.
49. Ridge, S. A.; Sluden, J.; Brown, O.; Robertson, L.; Wei, X.; Sapone, A.; Fernandez-Salguero, P. M.; Gonzalez, F. J.; Vreken, P.; Van Kuilenburg, A. B. P.; Van Gennip, A. H. and Mcleod, H. L. (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. 46, 151-156.
50. Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H.-J.; Leichman, C. G.; Leichman, L.; Diasio, R. B. and Danenberg, P. V. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylas. Clin. Cancer Res. 6, 1322-1327.
51. Seck, K.; Riemer, S.; Kates, R.; Ulrich, T.; Lutz, V.; Harbeck, N.; Schmitt, M.; Kiechle, M.; Diasiao, R. and Gross, E. (2005) Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 11, 5886-5892.
52. Sohn, D. R.; Cho, M. S. and Chung, P. J. (1999) Dihydropyrimidine dehydrogenase activity in a Korean population. Ther. Drug Monit. 21, 152-154.
53. Sumi, S.; Kidouchi, K.; Hayashi, K.; Imaeda, M.; Asai, M. and Wada, Y. (1998) Urinary screening for pyrimidine metabolism disorders: reference ranges for dihydrouracil, uracil, and dihydroduracil/uracil ratio. Adv. Exp. Med. Biol. 431, 191-195.
54. Suzen, H. S.; Yuce, N.; Guvenc, G.; Duydu, Y. and Erke, T. (2005) TYMS and DPYD polymorphisms in a Turkish population. Eur. J. Clin. Pharmacol. 61, 881-885.
55. Shestopal, S. A.; Johnson, M. R. and Diasio, R. B. (2000) Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim. Biophys. Acta 1494, 162-169.
56. Takai, K.; Fernandez-Salguero, P.; Kimura, S.; Gonzalez, F. J. and Yamada, K. (1994) Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hydridization. Genomics 24, 613-614.
57. Terashima, M.; Irinoda, T.; Kawamura, H.; Takagane, A.; Abe, K.; Oyama, K.; Fujiwara H. L.; Saito, K.; Gotoh, M. and Shirasaka, T. (2003) Intermittent FLDP:24-h infusion of 5-FU on days 1,3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale. Cancer Chemother. Pharmacol. 51, 240-246.
58. Tuchman, M.; Stoeckeler, J. S.; Kiang, D. T.; O'Dea, R. F.; Ramnaraine, B. S. and Mirkin, B. L. (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. New Engl. J. Med. 313, 245-249.
59. van Gennip, A. H.; Abeling, N. G. G. M.; Stroomer, A. E. M.; Van Lenthe, H. and Bakker, H. H. D. (1994) Clinical and biochemical findings in six patients with pyrimidine degradation dfects. J. Inher. Metab. Dis. 17, 130-132.
60. van Gennip, A. H.; Abeling, N. G. G. M.; Vreken, P. and Van Kuilenburg, A. B. P. (1997) Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J. Inher. Metab. Dis. 20, 203-213.
61. van Kuilenburg, A. B. P.; Poorter, R. L.; Peters, G. J.; Van Gennip, A. H.; Van Lenthe, H.; Stroomer, A. E.; Smid, K.; Noordhuis, P.; Bakker, P. J. and Veenhof, C. H. (1998) No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil. Adv. Exp. Med. Biol. 431, 811-816.
62. van Kuilenburg, A. B. P.; Vreken, P.; Abeling, N. G. G. M.; Bakker, H. D.; Meinsma, T.; Van Lenthe, H.; De Abreu, T. A.; Smeitink, J. A. M.; Kayserili, H.; Apak, M. Y.; Christensen, E.; Holopainen, I.; Pulkki, K.; Riva, D.; Botteon, G.; Holme, E.; Tulinius, M.; Kleijer, W. J.; Beemer, F. A.; Duran, M.; Niezen-Konning, K. D.; Smit, G. P. A.; Jakobs, D.; Smit, L. M. D.; Moog, U.; Spaapen, L. J. M. and Van Gennip, A. H. (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104, 1-9.
63. van Kuilenburg, A. B. P.; Haasjes, J.; Richel, D. J.; Zoetekouw, L.; Van Lenthe, A. H.; De Abreu, R. A.; Maring, J. G.; Vreken, P. and Van Gennip, A. H. (2000a) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 12, 4705-4712.
64. van Kuilenburg, A. B. P.; Van Lenthe, H.; Tromp, A.; Veltman, P. C. and Van Gennip, A. H. (2000b) Pit-falls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 46, 9-17.
65. van Kuilenbrug, A. B. P.; Muller, E. W.; Haasjes, J.; Meinsma, R.; Zoetekouw, L.; Waterham, H. R.; Baas, F.; Richel, D. J. and Van Gennip, A. H. (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res. 7, 1149-1153.
66. van Kuilenburg, A. B. P.; Dobritzsch, D.; Meinsma, R.; Haasjes, J.; Waterham, H. R.; Nowaczyk, M. J. M.; Maropoulos, G. D.; Hein, G.; Kalhoff, H.; Kirk, J. M.; Baaske, H.; Aukett, A.; Duley, J. A.; Ward, K. P.; Lindqvist, Y. and Van Gennip, A. H. (2002) Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem. J. 364, 157-163.
67. van Kuilenburg, A. B. P. (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40, 939-950.
68. van Kuilengurg, A. B. P.; Meinsma, R.; Beke, E.; Bobba, B.; Boffi, P.; Enns, G. M.; Witt, D. R. and Dobritzsch, D. (2005) Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. Biol. Chem. 386, 319-324.
69. van Kuilenburg, A. B. P. (2006) Screening for dihydropyrimidine dehydrogenase deficiency: To do or not to do, that's the question. Cancer Invest. 24, 215-217.
70. Vreken, P.; Van Kuilenburg, A. B. P.; Meinsma, J. R.; Smit, G. P.; Bakker, H. D.; De Abreu, R. A. and Van Gennip, A. H. (1996) A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J. Inherit. Metab. Dis. 19, 645-654.
71. Vreken, P.; Van Kuilenburg, A. B. P.; Meinsma, R.; De Abreu, R. A. and Van Gennip, A. H. (1997) Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum. Genet. 101, 333-338.
72. Vreken, P.; Van Kuilenburg, A. B. P.; Meinsma, R.; Haasjes, J.; Waterham, H. R.; Nowaczyk, M. J. J.; Maropoulos, G. D.; Hein, G.; Kalhoffs, H.; Kirke, J. M.; Baaske, H.; Auketta, A.; Duley, J. A.; Ward, K. P.; Lindqvist, Y. and Van Gennip, A. H. (1998) Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. Coli. J. Inherit. Metab. Dis. 21, 276-279.
73. Wei, X.; McLeod, H. L.; McMurrough, J.; Gonzalez, F. J. and Fernandez-Salguero, P. (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-Fluorouracil toxicity. J. Clin. Invest. 3, 610-615.
74. Wei, X.; Elizondo, G.; Sapone, A.; McLeod, H. L.; Raunio, H.; Fernandez-Salquero, P. and Gonzalez, F. J. (1998) Characterization of human dihydropyrimidine dehydrogenase gene. Genomics 51, 391-400.
75. Yamaguchi, K.; Arai, Y.; Kanda, Y. and Akagi, K. (2001) Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn. J. Cancer Res. 92, 337-342.
76. Yokota, H.; Fernandez-Salguero, P.; Furuya, H.; Lin, K.; McBride, O. W.; Podschun, G.; Schnckerz, K. D. and Gonzalez, F. J. (1994) cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem. 269, 23192-23196.